Have a feature idea you'd love to see implemented?
Let us know!
GLYC Glycomimetics Inc
Price (delayed)
$0.1798
Market cap
$11.59M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.61
Enterprise value
-$10.34M
GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate
Highlights
The debt has dropped by 65% year-on-year and by 29% since the previous quarter
The company's EPS rose by 6% YoY but it fell by 5% QoQ
Glycomimetics's equity has plunged by 63% YoY and by 31% from the previous quarter
GLYC's quick ratio is down by 42% YoY and by 13% QoQ
Key stats
What are the main financial stats of GLYC
Market
Valuations
Earnings
Shares outstanding
64.48M
Market cap
$11.59M
Enterprise value
-$10.34M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.58
Price to sales (P/S)
1,159.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1,034.31
Revenue
$10,000
EBIT
-$39.11M
EBITDA
-$38.26M
Free cash flow
-$35.72M
Per share
Balance sheet
Liquidity
EPS
-$0.61
Free cash flow per share
-$0.55
Book value per share
$0.31
Revenue per share
$0
TBVPS
$0.38
Total assets
$24.42M
Total liabilities
$4.36M
Debt
$448,775
Equity
$20.06M
Working capital
$19.5M
Debt to equity
0.02
Current ratio
5.48
Quick ratio
5.14
Net debt/EBITDA
0.57
Margins
Efficiency
Dividend
EBITDA margin
-382,618.5%
Gross margin
100%
Net margin
-391,132.3%
Operating margin
-408,770.5%
Return on assets
-99.6%
Return on equity
-116.8%
Return on invested capital
N/A
Return on capital employed
-195%
Return on sales
-391,132.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GLYC stock price
How has the Glycomimetics stock price performed over time
Intraday
8.97%
1 week
14.6%
1 month
9.3%
1 year
-84.63%
YTD
-92.38%
QTD
6.39%
Financial performance
How have Glycomimetics's revenue and profit performed over time
Revenue
$10,000
Gross profit
$10,000
Operating income
-$40.88M
Net income
-$39.11M
Gross margin
100%
Net margin
-391,132.3%
The net margin has declined by 4.9% since the previous quarter
Glycomimetics's net income has decreased by 4.9% QoQ and by 4.6% YoY
Glycomimetics's operating income has decreased by 4.1% YoY and by 3.6% from the previous quarter
The operating margin has declined by 3.6% since the previous quarter
Growth
What is Glycomimetics's growth rate over time
Valuation
What is Glycomimetics stock price valuation
P/E
N/A
P/B
0.58
P/S
1,159.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1,034.31
The company's EPS rose by 6% YoY but it fell by 5% QoQ
GLYC's price to book (P/B) is 84% lower than its last 4 quarters average of 3.4 and 69% lower than its 5-year quarterly average of 1.7
Glycomimetics's equity has plunged by 63% YoY and by 31% from the previous quarter
GLYC's P/S is 58% below its 5-year quarterly average of 2539.6
Efficiency
How efficient is Glycomimetics business performance
The ROE has plunged by 62% YoY and by 32% from the previous quarter
Glycomimetics's return on assets has shrunk by 59% YoY and by 30% QoQ
The company's return on sales fell by 4.9% QoQ
Dividends
What is GLYC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GLYC.
Financial health
How did Glycomimetics financials performed over time
The total assets has plunged by 61% YoY and by 29% from the previous quarter
GLYC's quick ratio is down by 42% YoY and by 13% QoQ
The debt is 98% smaller than the equity
The debt has dropped by 65% year-on-year and by 29% since the previous quarter
Glycomimetics's equity has plunged by 63% YoY and by 31% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.